Search in the Abstract Database

Search Abstracts 2013

* = Presenting author

P644. Factors associated to the presence of spondyloarthritis in patients with inflammatory bowel disease. AQUILES study

I. Marín-Jiménez1, F. Gómez2, M. Chaparro3, P. López4, M. Luján5, J. Gordillo6, P.M. Lastra1, S. Tabernero7, M. Andreu8, L. Cea Calvo9, R. García de Vicuña10, F. Vanaclocha11, C. Romero9, 1Gregorio Marañón Hospital, Spain, 2Reina Sofía Hospital, Spain, 3La Princesa Hospital & CIBEREHD, Spain, 4Alcorcón Foundation Hospital, Spain, 5Valencia General Hospital Consortium, Spain, 6Santa Creu i Sant Pau Hospital, Spain, 7Príncipe de Asturias Hospital, Spain, 8del Mar Hospital, Spain, 9Merck Sharp & Dohme de España, Spain, 10La Princesa Hospital IISP, Spain, 1112 de Octubre Hospital, Spain


Patients with inflammatory bowel disease (IBD) show frequent extra-intestinal manifestations and other immune diseases.


We describe the prevalence of spondyloarthritis (SpA) and the associated variables in a large sample of patients with IBD. Patients aged ≥18 years-old with known or newly diagnosed IBD were recluted. Clinical data were collected through direct interview and from patient's clinical record. Multivariate models including age, sex, durations of disease, presence of other extraintestinal manifestations, psoriasis, age at diagnosis, location of disease and classification, were developed to assess the independent factors related to the presence of SpA at baseline.


478 patients were recruited (mean age: 40.9 years-old [14.2]; 52.7% females; mean disease duration 3 years [IQR: 0–9]; 278 [58.2%] CD, 193 [40.4%] UC and 7 [1.5%] indeterminate colitis). In CD patients, the prevalence of SpA was 12.9%. In the multivariate model variables with the highest adjusted effect on the prevalence of SpA were duration of disease ≥8 years (OR: 2.2 [95% CI: 0.7–6.9]) or 4–7 years (OR: 2.5 [0.8–8.1]), psoriasis (OR: 2.0 [0.4–10.2]) and extra-intestinal manifestations (OR: 2.1 [0.9–4.9]), but only extra-intestinal manifestations (OR: 2.2 [1.0–4.6]) remained as independent. The prevalence of SpA in UC patients was 5.7%. In the multivariable model the highest adjusted effect was for duration of disease (OR 1.06 [1.00–1.13] per year of duration), psoriasis (OR 29.3 [1.6–544.1]), and extension (E2 – left colitis: OR 5.6 [1.2–26.9] compared to E1 – ulcerative proctitis), and they remained as independent in the model. The results are limited by the low prevalence of some variables, like psoriasis, leading to wide confidence intervals.


In patients with CD recruited for the AQUILES study in Spain, the presence of SpA was associated to other extra-intestinal manifestations while in patients with UC it was associated to duration of disease, psoriasis and extension of disease.